Merck Stock: Attractive Dividend Play at Current Levels

Investing.com | Oct 13, 2021 at 10:17 AM
  • Is one of the largest international healthcare companies, focusing on delivering innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health products, and other related pharmaceuticals.
  • Subsequent to the Organon spinoff, Merck estimates revenues of $46.4 billion to $47.4 billion for the year (previously $45.8 billion to $47.8 billion).
  • At the midpoint of this EPS estimate ($5.52), the stock is currently trading with a (sort of forward) P/E of 14.4 attached.